All Outputs (2)

A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol (2019)
Journal Article
Wright, C., Hart, S. P., Allgar, V., English, A., Swan, F., Dyson, J., Richardson, G., Twiddy, M., Cohen, J., Hussain, J., Johnson, M., Hargreaves, I., & Crooks, M. G. (2019). A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol. ERJ Open Research, 5(4), Article 0186. https://doi.org/10.1183/23120541.00186-2019

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that causes breathlessness and cough that worsen over time, limiting daily activities and negatively impacting quality of life. Although treatments are now av... Read More about A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol.

The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: A randomised placebo-controlled study (2019)
Journal Article
Morice, A. H., Kitt, M. M., Ford, A. P., Tershakovec, A. M., Wu, W. C., Brindle, K., Thompson, R., Thackray-Nocera, S., & Wright, C. (2019). The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: A randomised placebo-controlled study. European respiratory journal, 54(1), Article 1900439. https://doi.org/10.1183/13993003.00439-2019

We evaluated the effect of gefapixant on cough reflex sensitivity to evoked tussive challenge.

In this phase 2, double-blind, two-period study, patients with chronic cough (CC) and healthy volunteers (HV) were randomised to single-dose gefapixant... Read More about The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: A randomised placebo-controlled study.